Rocket Pharma Q1 net loss $47.6M; KRESLADI gets FDA accelerated approval; PRV sold for $180M

ROCKET PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$0.42

Net loss of $47.6M ($0.42/sh) narrowed from $61.3M ($0.56/sh) YoY.
Cash $144.4M + $180M PRV proceeds extend runway into Q2 2028.
FDA granted accelerated approval for KRESLADI in severe LAD-I in March 2026.
Monetized Rare Pediatric Disease PRV for $180M on April 28, 2026.
Pivotal Phase 2 trial of RP-A501 for Danon disease dosing reinitiated; RP-A701 first dosing expected mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKET PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: net income Net loss was $47.6 million or $0.42 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.42 per share (basic and diluted).

Period: the first quarter ended March 31, 2026
Net income: Net loss was $47.6 million or $0.42 per share (basic and diluted) for the three months ended March 31, 2026
EPS: $0.42 per share (basic and diluted)
Result: reported results

Exact text from the filing

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-019573

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.